Literature DB >> 2163115

The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes.

L A Koutsky1, R L Ashley, K K Holmes, C E Stevens, C W Critchlow, N Kiviat, C M Lipinski, P Wølner-Hanssen, L Corey.   

Abstract

To evaluate the prevalence of symptomatic versus asymptomatic or unrecognized type 2 herpes simplex virus (HSV-2) infection, the authors performed physical examination, viral cultures, and type-specific serologic assays in 776 randomly selected women attending an STD clinic and 636 female university students. Forty-six percent of women attending the STD clinic compared with 8.8% of the university students had serologic evidence of HSV-2 infection. Clinical or historical evidence of genital herpes was present in only 34% of the HSV-2 seropositive women attending the STD clinic and in 29% of the HSV-2 seropositive women attending the university clinic. Among women attending the STD clinic, the prevalence of recognized genital infection was more common among those with HSV-2 antibodies only versus those with HSV-1 and -2 antibodies (odds ratio = 2.39; 95% confidence interval = 1.30-4.37), suggesting that HSV-1 infection reduces the likelihood of recognizing HSV-2 infection. In view of the high proportion of seropositive individuals with unrecognized HSV-2 infection in both high and low prevalence HSV-2 seropositive populations, newly developed HSV type-specific serologic methods should be evaluated for detecting carriers of HSV-2 infection and counseling these individuals about strategies for avoiding sexual and perinatal transmission of HSV-2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163115     DOI: 10.1097/00007435-199004000-00009

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  36 in total

1.  Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.

Authors:  S Q Wales; C C Smith; M Wachsman; G Calton; L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Highly sensitive enhanced chemiluminescence immunodetection method for herpes simplex virus type 2 Western immunoblot.

Authors:  J Dalessio; R Ashley
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

Review 3.  Ethics of screening for asymptomatic herpes virus type 2 infection.

Authors:  Ingela Krantz; Gun-Britt Löwhagen; Beth Maina Ahlberg; Tore Nilstun
Journal:  BMJ       Date:  2004-09-11

4.  Herpes simplex type 2 infection in a cohort aged 21 years.

Authors:  J Eberhart-Phillips; N P Dickson; C Paul; J P Fawcett; D Holland; J Taylor; A L Cunningham
Journal:  Sex Transm Infect       Date:  1998-06       Impact factor: 3.519

5.  Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2.

Authors:  D S Schmid; D R Brown; R Nisenbaum; R L Burke; D Alexander; R Ashley; P E Pellett; W C Reeves
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

6.  Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies.

Authors:  R L Ashley; L Wu; J W Pickering; M C Tu; L Schnorenberg
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

7.  Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study.

Authors:  Timothy W Schacker; Marcus Conant; Christopher Thoming; Tamara Stanczak; Zengri Wang; Michael Smith
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Cervical antibodies in patients with oral herpes simplex virus type 1 (HSV-1) infection: local anamnestic responses after genital HSV-2 infection.

Authors:  R Ashley; A Wald; L Corey
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways.

Authors:  Maria Dulfary Sanchez; Augusto C Ochoa; Timothy P Foster
Journal:  Antiviral Res       Date:  2016-05-15       Impact factor: 5.970

10.  Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfected adults: an observational cohort study.

Authors:  Darrell H S Tan; Janet M Raboud; Rupert Kaul; Sharon L Walmsley
Journal:  BMJ Open       Date:  2014-01-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.